Thoughts on the Market
2026-09-15 · Hosted by Mike Wilson · Morgan Stanley
Executive Summary
Morgan Stanley analysts Erin Wright (US Healthcare Services) and Terence Flynn (US BioPharma) discussed a structural shift toward patient-directed healthcare, recorded on the sidelines of Morgan Stanley's 24th Annual Healthcare Conference. Flynn described a "parallel access infrastructure" emerging alongside traditional insurance, where patients can start treatment, get a prescription via telehealth, and fill it through non-traditional channels — already true for more than 25 branded drugs sold directly to consumers at cash prices.
Key Stories & Changes
1. Direct-to-Consumer Pharma Opportunity Sized at $26 Billion
Manufacturers already sell more than 25 branded drugs directly to patients at cash prices
Terence Flynn's model sizes the total addressable market at $26 billion in peak US sales, about 3% of total branded pharmaceutical spend
GLP-1/obesity drugs account for roughly half of that $26 billion opportunity
Four criteria determine DTC suitability: self-administration, no in-person diagnosis needed, lower price point, and no FDA REMS legal restrictions
2. GLP-1s Proved the DTC Model Works Because of a Coverage Gap
Only about 50% of US employer health plans currently cover obesity medications, creating the gap that pushed patients toward cash-pay and telehealth channels
Other categories seen as amenable to the same model: migraine treatment, oral PCSK9 therapies, topical dermatology, non-opioid pain
Oncology explicitly excluded as a DTC candidate given very high existing insurance coverage rates
3. Consumers Are Paying Out of Pocket at Higher Rates Than Expected
Morgan Stanley's AlphaWise survey found 25% of consumers paid entirely out of pocket for at least one healthcare service in the past year — higher than the team expected
Behavioral and mental health services were the most common category, cited by about 8% of the surveyed cohort
Average annual out-of-pocket spend was about $908, but maximum willingness to spend was roughly double that, signaling room for further growth
34% of consumers have taken a voluntary wellness lab test in the past three years; roughly two-thirds already own or plan to buy a wearable device
4. Diversified Managed Care Companies Best Positioned to Benefit
Erin Wright argues insurers with the most consumer touch points — across insurance, provider, technology, and pharmacy assets — are best positioned to adapt to rising consumerism
Clinical laboratories are increasingly partnering with wearable makers to offer subscription-based biomarker panels, making wearable data more clinically actionable
Trends Identified
1. A Parallel Access Channel Is Forming Alongside Traditional Insurance
Rather than replacing insurance, biopharma and healthcare services are building a second track — telehealth-initiated prescriptions, cash-pay channels, digital front doors — specifically for high-friction, viable-cash-price categories, letting patients bypass traditional intermediation without displacing the core insurance system.
2. Coverage Gaps Are the Key Enabler of DTC Growth
The GLP-1 experience shows DTC models emerge where insurance coverage is incomplete rather than where consumer demand alone is highest — meaning future DTC expansion will likely track wherever new coverage gaps appear, not simply drug popularity. ---
Sentiment Analysis
Overall Market Sentiment: Constructive
Both analysts frame the shift toward patient-directed healthcare as a durable structural trend already showing up in survey data and manufacturer behavior, rather than a speculative future scenario.
Risk Factors Highlighted
Insurance coverage gaps as a double-edged sword: The same gaps driving DTC growth also reflect unmet patient need that could invite future regulatory scrutiny.
REMS and legal restrictions limit DTC applicability: FDA prescribing restrictions on certain drug classes exclude them from the direct-access model regardless of demand.
Category concentration risk: Roughly half of the DTC opportunity is concentrated in GLP-1s, making the broader thesis sensitive to that single category's trajectory.
This episode was covered in today's [The Market Signal — 2026-09-15](https://marketsignal.beehiiv.com/p/the-market-signal-2026-09-15), a cross-source synthesis of multiple podcast reports.